GlassScriptPhysician profile
David K Imagawa
NPI 1467532630
$55,600.25
in general payments reported to CMS, 2019-2025
29 companies · $7,929 in 2025
The $7,929 reported for 2025 was more than what 94% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $554 · 2021: $10K · 2022: $5,111 · 2023: $8,443 · 2024: $5,033 · 2025: $7,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $3,296 · Travel and Lodging: $33.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,075.00 |
| Food and Beverage | $3,296.08 |
| Travel and Lodging | $33.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $13,898.27 | 2021-2022 | |
| Dilon Technologies, INC. | $10,552.87 | 2022-2025 | Hemoblast Bellows |
| Biom'Up Sa | $9,480.16 | 2019 | |
| Eisai INC. | $9,136.04 | 2019-2021 | |
| Davol INC. | $3,500.00 | 2024 | |
| Genentech USA, INC. | $3,330.32 | 2023 | Tecentriq |
| Becton, Dickinson and Company | $1,800.00 | 2023 | |
| Ethicon US, LLC | $828.65 | 2024-2025 | Stratafix, Pds, Vistaseal |
| Abbvie INC. | $391.21 | 2024-2025 | |
| Dova Pharmaceuticals | $315.97 | 2020-2021 | |
| Angiodynamics, INC. | $289.03 | 2019-2023 | Nanoknife |
| Intra-Sana Laboratories | $250.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $235.07 | 2025 | Imfinzi |
| Galvanize Therapeutics, INC | $225.78 | 2024 | Aliya System |
| Abk Biomedical USA, INC. | $192.85 | 2024 | Eye90 Microspheres |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biom'Up France Sas | $157.61 | 2021 | |
| Medtronic, INC. | $150.00 | 2022-2025 | Lapro-Clip, Gia |
| Boston Scientific Corporation | $140.19 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Sobi, INC | $135.99 | 2022 | |
| Heron Therapeutics, INC. | $113.74 | 2019 | |
| Mallinckrodt Hospital Products INC. | $97.19 | 2024 | Terlivaz |
| Solventum Corporation | $97.10 | 2024 | Prevena, Spoton, V.A.C. Veraflo Cleanse Choice |
| Exelixis INC. | $93.85 | 2019 | |
| Gilead Sciences, INC. | $63.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.50 | 2022 | |
| Baxter Healthcare | $41.67 | 2020 | |
| Cook Medical LLC | $40.04 | 2019-2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Imagawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.